|
Objective: To investigate Kangxin capsule on hyperlipidemia steatohepatitis . Methods: 40 purebred male New Zealand white rabbits , high - cholesterol diet for 10 weeks in steatohepatitis model of hyperlipidemia . 40 the purebred male New Zealand white rabbits were randomly divided into five groups: model group ( high fat diet ) ; the atorvastatin calcium group ( high fat diet atorvastatin calcium 2.5 mg / kg / d ) ; Kangxin Capsule low-dose group ( high-fat diet Kangxin capsule 0.4g/kg/d); Kangxin capsule high dose group ( Kangxin Capsule 1.6g/kg/d); controls ( normal diet ) . Were killed after 10 weeks , the use of multi-functional biochemical changes in liver function , and lipid were measured ; immunohistochemical techniques were used to detect the tumor necrosis factor - α ( TNF -α ) , transforming growth factor - β ( TGF - β) protein in the expression of the liver , and the correlation analysis , RT - PCR method to detect groups liver homogenate TNF-α, TGF-β mRNA levels , hyperlipidemia steatohepatitis liver morphology observed in the light microscope and analysis . Results: Kangxin Capsule intervention group of animals , improved liver function , lipid lowering effect of the high-dose group better . the (p lt; 0.05, P lt; 0.01), liver tissue TNF-α and TGF-β protein content compared with the model group (p lt; 0.05, P lt; 0.01), and both have a correlation (P lt ; 0.01 ) ; of TNF -αmRNA and TGF-βmRNA , compared with the model group lowered (p lt; 0.05, P lt; 0.01). Conclusion Kangxin Capsule can reduce cholesterol , triglycerides , low-density lipoprotein cholesterol , improve liver function , reduce the degree of liver fat , lower TNF -α , TGF -β expression in the liver tissue . Lowered the level of TNF-αmRNA, TGF-βmRNA help reduce low-fat in fatty liver hepatitis and to promote their recovery .
|